Arid1a	O
regulates	O
response	O
to	O
anti	O
-	O
angiogenic	O
therapy	O
in	O
advanced	O
hepatocellular	O
carcinoma	O
.	O


BACKGROUND	O
&	O
AIMS	O
:	O
AT	O
-	O
rich	O
interaction	O
domain	O
1a	O
(	O
Arid1a	O
)	O
,	O
a	O
component	O
of	O
the	O
chromatin	O
remodeling	O
complex	O
,	O
has	O
emerged	O
as	O
a	O
tumor	O
suppressor	O
gene	O
.	O


It	O
is	O
frequently	O
mutated	O
in	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
.	O


However	O
,	O
it	O
remains	O
unknown	O
how	O
Arid1a	O
suppresses	O
HCC	O
development	O
and	O
whether	O
Arid1a	O
deficiency	O
could	O
be	O
exploited	O
for	O
therapy	O
,	O
we	O
aimed	O
to	O
explore	O
these	O
questions	O
.	O


METHODS	O
:	O
The	O
expression	O
of	O
Arid1a	O
in	O
human	O
and	O
mouse	O
HCCs	O
was	O
determined	O
by	O
immunohistochemical	O
(	O
IHC	O
)	O
staining	O
.	O


Gene	O
expression	O
was	O
determined	O
by	O
quantitative	O
PCR	O
,	O
ELISA	O
or	O
western	O
blotting	O
.	O


Arid1a	O
knockdown	O
HCC	O
cell	O
lines	O
were	O
established	O
by	O
lentiviral	O
-	O
based	O
shRNA	O
.	O


Tumor	O
angiogenesis	O
was	O
quantified	O
based	O
on	O
vessel	O
density	O
.	O


The	O
regulation	O
of	O
angiopoietin	O
(	O
Ang2	O
)	O
expression	O
by	O
Arid1a	O
was	O
identified	O
by	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
.	O


The	O
tumor	O
promoting	O
function	O
of	O
Arid1a	O
loss	O
was	O
studied	O
with	O
a	O
xenograft	O
model	O
in	O
nude	O
mice	O
and	O
diethylnitrosamine	O
(	O
DEN	O
)	O
-	O
induced	O
HCC	O
in	O
Arid1a	O
conditional	O
knockout	O
mice	O
.	O


The	O
therapeutic	O
values	O
of	O
Ang2	O
antibody	O
and	O
sorafenib	O
treatment	O
were	O
evaluated	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O


RESULTS	O
:	O
We	O
demonstrate	O
that	O
Arid1a	O
deficiency	O
,	O
occurring	O
in	O
advanced	O
human	O
HCCs	O
,	O
is	O
associated	O
with	O
increased	O
vessel	O
density	O
.	O


Mechanistically	O
,	O
loss	O
of	O
Arid1a	O
causes	O
aberrant	O
histone	O
H3K27ac	O
deposition	O
at	O
the	O
angiopoietin	B-ENHANCER
-	I-ENHANCER
2	I-ENHANCER
(	I-ENHANCER
Ang2	I-ENHANCER
)	I-ENHANCER
enhancer	E-ENHANCER
and	O
promoter	O
,	O
which	O
eventually	O
leads	O
to	O
ectopic	O
expression	O
of	O
Ang2	O
and	O
promotes	O
HCC	O
development	O
.	O


Ang2	O
blockade	O
in	O
Arid1a	O
-	O
deficient	O
HCCs	O
significantly	O
reduces	O
vessel	O
density	O
and	O
tumor	O
progression	O
.	O


Importantly	O
,	O
sorafenib	O
treatment	O
,	O
which	O
suppresses	O
H3K27	O
acetylation	O
and	O
Ang2	O
expression	O
,	O
profoundly	O
halts	O
the	O
progression	O
of	O
Arid1a	O
-	O
deficient	O
HCCs	O
.	O


CONCLUSIONS	O
:	O
Arid1a	O
-	O
deficiency	O
activates	O
Ang2	O
-	O
dependent	O
angiogenesis	O
and	O
promotes	O
HCC	O
progression	O
.	O


Loss	O
of	O
Arid1a	O
in	O
HCCs	O
confers	O
sensitivity	O
to	O
Ang2	O
blockade	O
and	O
sorafenib	O
treatment	O
.	O


LAY	O
SUMMARY	O
:	O
AT	O
-	O
rich	O
interaction	O
domain	O
1a	O
(	O
Arid1a	O
)	O
,	O
is	O
a	O
tumor	O
suppressor	O
gene	O
.	O


Arid1a	O
-	O
deficiency	O
promotes	O
Ang2	O
-	O
dependent	O
angiogenesis	O
leading	O
to	O
hepatocellular	O
carcinoma	O
progression	O
.	O


Arid1a	O
-	O
deficiency	O
also	O
sensitizes	O
tumors	O
to	O
Ang2	O
blockade	O
by	O
sorafenib	O
treatment	O
.	O
